H.C. Wainwright assumed coverage of Xeris Biopharma (XERS) with a Buy rating and $10 price target The firm believes the commercial potential of the company’s commercial portfolio remains “meaningfully underappreciated.” The portfolio has the potential to drive further Xeris stock appreciation, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XERS: